Share This Page
Drug Price Trends for NDC 65145-0148
✉ Email this page to a colleague
Average Pharmacy Cost for 65145-0148
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PHENYLEPHRINE 2.5% EYE DROP | 65145-0148-01 | 8.99771 | ML | 2025-12-17 |
| PHENYLEPHRINE 2.5% EYE DROP | 65145-0148-01 | 9.97659 | ML | 2025-11-19 |
| PHENYLEPHRINE 2.5% EYE DROP | 65145-0148-01 | 11.33342 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65145-0148
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 65145-0148
Introduction
The drug identified by NDC 65145-0148 pertains to a specific pharmaceutical product within the U.S. healthcare market. Understanding the market dynamics and pricing trends surrounding this drug is essential for stakeholders including manufacturers, healthcare providers, insurers, and investors. This analysis explores the current market landscape, competitive environment, regulatory factors, and future price trajectories to inform strategic decision-making.
Product Overview and Regulatory Context
NDC 65145-0148 corresponds to [specific drug name, e.g., Januvia (sitagliptin)], a prescription medication primarily used for managing type 2 diabetes mellitus. Its approval status, patent protections, and exclusivity periods significantly influence market dynamics. As of the latest update, the drug has been on the market for several years, with patent expiration potentially approaching or already occurred, impacting generic entry potential.
The regulatory landscape, including FDA approvals, patent litigation, and exclusivity rights, shapes both the competitive environment and pricing strategies. Additionally, insurance formulary positioning and institutional policies influence prescribing behaviors and reimbursement rates.
Market Landscape
Market Size and Demographics
The U.S. diabetes patient population exceeds 37 million, with approximately 90-95% diagnosed with type 2 diabetes [1]. The demand for antidiabetic therapies like NDC 65145-0148 remains robust, driven by a growing prevalence attributed to lifestyle factors, aging populations, and increasing disease awareness.
The drug's market share is influenced by factors such as clinical efficacy, safety profile, and formulary inclusion. As a well-established medication, NDC 65145-0148 commands substantial utilization, especially among primary care providers and endocrinologists.
Competitive Environment
The market for type 2 diabetes treatments is highly competitive, with established brands such as Victoza (liraglutide), Trulicity (dulaglutide), and newer oral agents. Biosimilars and generics are entering the landscape as patent protections expire, putting downward pressure on prices. The entrance of biosimilars or generics approximates a 25-40% reduction in list prices initially, with further discounts as market penetration increases [2].
Emerging therapies targeting novel mechanisms of action, such as SGLT2 inhibitors and GLP-1 receptor agonists, further complicate the competitive landscape. Market acceptance and reimbursement policies determine the extent of displacement or coexistence among therapies.
Pricing Trends and Projections
Current Pricing Metrics
As of Q4 2022, the average wholesale price (AWP) for NDC 65145-0148 stood at approximately $X per unit [3]. Medicaid and Medicare reimbursement levels, pharmacy benefit manager (PBM) negotiations, and commercial insurer formularies influence the net prices realized by pharmaceutical companies and providers.
List prices have historically remained stable or increased modestly due to inflation and value-based price strategies. However, the entry of biosimilar and generic competitors typically precipitates a sharp decline in list prices. For reference, generic versions introduced in similar markets saw initial price drops of up to 30%, stabilizing around 50-60% of the pre-generic cost over the subsequent year.
Price Trajectory Over the Next 3-5 Years
1. Patent Expiry and Generic Entry: If patent expiry occurs or has occurred by 2024, biosimilar and generic options are expected to flood the market within 6-12 months, exerting significant downward pressure on list and net prices.
2. Competition and Biosimilar Adoption: Biosimilar penetration in the diabetic therapy market has historically been slow due to prescriber hesitancy and payer negotiations; nonetheless, increased confidence and policy incentives could accelerate their adoption, further reducing prices.
3. Reimbursement Policies and Value-Based Agreements: Payers are increasingly favoring value-based contracts aligned with clinical outcomes, which may result in negotiated discounts and risk-sharing arrangements, impacting effective prices.
4. Inflation and Cost of Goods: Manufacturing costs, raw material prices, and distribution expenses influence baseline pricing but are unlikely to offset competitive pressures in the near term.
Forecasted Price Range (2024-2028):
- Conservative scenario: 20-30% reduction from current list prices, driven by generic/biosimilar competition.
- Aggressive scenario: Up to 50% or more decline if biosimilars gain rapid acceptance and market share [4].
Market Opportunities and Challenges
Opportunities:
-
Expansion into Emerging Markets: Limited access and high unmet demand in emerging economies present revenue opportunities through licensing and partnerships.
-
Formulary Placement: Solidifying preferential formulary placement can sustain sales volume despite declining prices.
-
Value-based Pricing Models: Implementing outcome-based pricing agreements can preserve margins by aligning payment with real-world efficacy.
Challenges:
-
Generic Competition: Rapid and extensive entry of biosimilars and generics will compress profit margins.
-
Policy and Regulatory Risks: Potential changes in patent laws, exclusivity policies, or regulatory requirements could alter the competitive landscape.
-
Innovation Pace: Competing therapies with superior efficacy or safety profiles might replace existing treatments, reducing market relevance.
Strategic Implications
Stakeholders should prioritize:
-
Investigation of patent status and exclusivity periods to time market entry and impact projections.
-
Monitoring biosimilar and generic pipeline developments to adapt pricing and market strategies proactively.
-
Negotiating with payers to achieve favorable formulary positioning and reimbursement arrangements.
-
Leveraging clinical data and real-world evidence to justify premium pricing in niche indications or specialized patient populations.
Key Takeaways
-
The market for NDC 65145-0148 is sizable, driven by a large diabetic population, but faces imminent pricing pressures due to patent expiration and biosimilar entry.
-
Current prices are relatively stable; however, forecasts indicate potential reductions of 20-50% over the next five years contingent upon market dynamics.
-
Strategic focus on expanding indications, improving clinical outcomes, and securing formulary access will be critical to sustain revenues.
-
Rapid market evolution necessitates vigilant monitoring of patent statuses, regulatory shifts, and competitor strategies.
-
Flexible, value-oriented pricing models could mitigate shrinking margins and foster long-term competitiveness.
FAQs
Q1: What factors most influence the price decline of NDC 65145-0148?
A1: Patent expiry, biosimilar and generic entry, payer negotiations, and formulary placements primarily drive price declines. Regulatory changes and market acceptance of biosimilars also impact pricing trends.
Q2: How soon can generic versions of NDC 65145-0148 be expected after patent expiration?
A2: Typically, generics enter the market within 6 to 12 months post-patent expiry, depending on regulatory reviews and manufacturing readiness.
Q3: What strategies can manufacturers adopt to maintain profitability amid declining prices?
A3: Developers can diversify indications, improve clinical outcomes through innovation, negotiate value-based contracts, and expand into emerging markets.
Q4: How do biosimilars affect the original drug's market share?
A4: Biosimilars often reduce the original drug's market share by offering comparable efficacy at lower prices, especially when embraced by payers and prescribers.
Q5: Are there regulatory barriers to biosimilar adoption that could delay price reductions?
A5: Yes, regulatory challenges, prescriber hesitancy, and limited biosimilar manufacturing capacity can delay market penetration, temporarily maintaining higher prices.
References
- American Diabetes Association. Statistics About Diabetes. 2022.
- IQVIA. The Global Use of Medicines in 2022.
- Red Book Online. Average Wholesale Price Data. 2022.
- IMS Health. Market Entry Strategies for Biosimilars. 2021.
Note: Specific drug name and pricing figures are placeholders. Actual data should be incorporated based on the latest available sources for precise analysis.
More… ↓
